Evidence map›Paper›PMID 25154978›Full record

ReviewNature reviews. Cardiology2014

Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.

Glenn N Levine, Young-Hoon Jeong, Shinya Goto, Jeffrey L Anderson, Yong Huo, Jessica L Mega, Kathryn Taubert, Sidney C Smith

Registry-linked trialAbstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04937699 (Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome), which is not on this map. Cited by 154 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04937699 phase4recruitingnot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome

TypeinterventionalSponsorSecond Affiliated Hospital, Zhejiang University, School of MedicineRan2023 to 2026Enrolled2,690ConditionsAcute Coronary Syndrome, Percutaneous Coronary InterventionArmsStandard-DAPT of Ticagrelor plus aspirin, Sequential monotherapy of Ticagrelor and clopidogrel
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Durable polymer versus biodegradable polymer drug-eluting stents in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Body weight rather than unfractionated heparin dose predicts periprocedural bleeding during elective PCI.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Article
  20. Review

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Glenn N LevineBaylor College of Medicine and Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030, USA.
Young-Hoon JeongGyeongsang National University Hospital and Gyeongsang National University School of Medicine, 79, Gangnam-ro, Jinju-si, Gyeongsangnam-do, 660-702, South Korea.
Shinya GotoDepartment of Medicine (Cardiology), Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1143, Japan.
Jeffrey L AndersonIntermountain Medical Center, University of Utah School of Medicine, 5121 South Cottonwood Street, Murray, UT 84157, USA.
Yong HuoDepartment of Cardiology, Peking University First Hospital, Xueyuan Road, Haidian District, Beijing, 100083, China.
Jessica L MegaBrigham and Women's Hospital, TIMI Study Group, 350 Longwood Avenue, Boston, MA 02115, USA.
Kathryn TaubertWorld Heart Federation, 32, rue de Malatrex, 1201 Geneva, Switzerland.
Sidney C SmithDivision of Cardiology, University of North Carolina, 160 Dental Circle, CB 7075, Chapel Hill, NC 27599, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI) have been formulated by both the ACC/AHA and the ESC. These recommendations are based primarily on large, phase III, randomized, controlled trials of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor. However, few East Asian patients have been included in the trials to assess the use of these agents, particularly the newer agents prasugrel and ticagrelor. Additionally, an increasing body of data suggests that East Asian patients have differing risk profiles for both thrombophilia and bleeding compared with white patients, and that a different 'therapeutic window' of on-treatment platelet reactivity might be appropriate in East Asian patients. Furthermore, a phenomenon referred to as the 'East Asian paradox' has been described, in which East Asian patients have a similar or even a lower rate of ischaemic events after PCI compared with white patients, despite a higher level of platelet reactivity during DAPT. Recognizing these concerns, the World Heart Federation has undertaken this evidence-based review and produced this expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients.

Indexed as

ConsensusPercutaneous Coronary InterventionPractice Guidelines as TopicAcute Coronary SyndromeAsia, EasternCause of DeathHumansPlatelet Aggregation InhibitorsSurvival RatePlatelet Aggregation Inhibitors

Identifiers

PMID25154978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.